- Home
- XNCR vs INBX Comparison
XNCR vs INBX Comparison
Compare XNCR & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XNCR | INBX |
|---|---|---|
| Founded | 1997 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 881.9M | 999.7M |
| IPO Year | 2013 | 2024 |
Fundamental Metrics
Financial Performance| Metric | XNCR | INBX |
|---|---|---|
| Price | $11.93 | $101.83 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 3 |
| Target Price | $22.33 | ★ $150.00 |
| AVG Volume (30 Days) | ★ 648.0K | 442.3K |
| Earning Date | 05-08-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 65.36 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $125,576,000.00 | $1,300,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.80 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 13.65 | ★ 550.00 |
| 52 Week Low | $6.92 | $12.80 |
| 52 Week High | $18.69 | $155.29 |
Technical Indicators
Market Signals| Indicator | XNCR | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 48.54 | 46.06 |
| Support Level | $10.83 | $99.20 |
| Resistance Level | $12.87 | $153.14 |
| Average True Range (ATR) | 0.58 | 11.52 |
| MACD | 0.02 | -3.07 |
| Stochastic Oscillator | 46.07 | 8.97 |
Price Performance
Historical ComparisonAbout XNCR Xencor Inc.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.